Details for New Drug Application (NDA): 011707
✉ Email this page to a colleague
NDA 011707 describes OPANA, which is a drug marketed by Endo Pharms and Endo Operations and is included in four NDAs. There are three patents protecting this drug and six Paragraph IV challenges. Additional details are available on the OPANA profile page.
The generic ingredient in OPANA is oxymorphone hydrochloride. There are nine drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the oxymorphone hydrochloride profile page.
The generic ingredient in OPANA is oxymorphone hydrochloride. There are nine drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the oxymorphone hydrochloride profile page.
Summary for 011707
| Tradename: | OPANA |
| Applicant: | Endo Pharms |
| Ingredient: | oxymorphone hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 011707
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 1.5MG/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 1MG/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
